TB-PRACTECAL
2022
Short All-Oral Regimens for Rifampicin-Resistant TB
In 552 patients with rifampicin-resistant tuberculosis, a 24-week regimen of bedaquiline, pretomanid, linezolid and moxifloxacin improved favourable outcome at 72 weeks compared with the 9–20-month standard of care.
Result
- Absolute difference
- 37 points
- NNT
- 3
risk difference-3796.6% CI -53 to -22
Absolute difference and NNT are derived from the event rates.
Also reported: mITT: 89 % vs 52 % favourable ; noninferior, better safety with BPaLM.
- Subtopic
- MDR-TB
- Design
- Open-label RCT
- Enrolled
- 301 patients
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Nyang'wa BT, et al. N Engl J Med. 2022;387(25):2331-2343.doi 10.1056/NEJMoa2117166
Discussion & critique
Generational shift in MDR-TB care: 6-month all-oral BPaLM replaces 18–24-month injectable-based regimens. Now the WHO-preferred therapy for MDR-TB without fluoroquinolone resistance.